Hu Wei-Syun, Lin Cheng-Li
School of Medicine, College of Medicine, China Medical University, Taichung, 40402, Taiwan.
Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, 2, Yuh-Der Road, Taichung, 40447, Taiwan.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 12. doi: 10.1007/s00210-025-04272-y.
We investigated whether there is an association between using antidiabetic agents (ADAs) or insulin and hemorrhoid risk among people with diabetes mellitus (DM). We have essentially used a massive dataset to identify a statistical association between ADAs and hemorrhoidal disease. The hazard ratios (HRs) and 95% confidence intervals (CIs) for hemorrhoids were estimated using univariate and multivariate Cox proportional hazards models. Covariates used in the multivariate models included age, sex, comorbidities, and medications. A total of 126,897 patients who had DM between 2009 and 2016 were involved in this study. The joint effect analysis showed that anyone receiving medication therapy with dipeptidyl peptidase IV (DPP IV) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i) can significantly lower the risk of hemorrhoid with the adjusted HR (aHR) of 0.64, 95% CI=0.62-0.67; aHR of 0.29, 95% CI=0.24-0.35; and aHR of 0.14, 95% CI=0.11-0.18, respectively. We found that SGLT2i is more potent for hemorrhoid prophylaxis in incidence rate among DM patients.
我们调查了糖尿病患者使用抗糖尿病药物（ADAs）或胰岛素与痔疮风险之间是否存在关联。我们主要使用了一个大规模数据集来确定ADAs与痔疮疾病之间的统计关联。使用单变量和多变量Cox比例风险模型估计痔疮的风险比（HRs）和95%置信区间（CIs）。多变量模型中使用的协变量包括年龄、性别、合并症和药物。共有126897名在2009年至2016年期间患有糖尿病的患者参与了本研究。联合效应分析表明，接受二肽基肽酶IV（DPP IV）抑制剂、胰高血糖素样肽-1受体激动剂（GLP-1 RAs）和钠-葡萄糖协同转运蛋白-2抑制剂（SGLT2i）药物治疗的任何人都可以显著降低痔疮风险，调整后的HR（aHR）分别为0.64，95%CI = 0.62 - 0.67；aHR为0.29，95%CI = 0.24 - 0.35；aHR为0.14，95%CI = 0.11 - 0.18。我们发现，SGLT2i在预防糖尿病患者痔疮发病率方面更有效。
